DK2861599T3 - Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme - Google Patents
Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme Download PDFInfo
- Publication number
- DK2861599T3 DK2861599T3 DK13731218.7T DK13731218T DK2861599T3 DK 2861599 T3 DK2861599 T3 DK 2861599T3 DK 13731218 T DK13731218 T DK 13731218T DK 2861599 T3 DK2861599 T3 DK 2861599T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrazolopyrimidines
- pyrrolo
- auto
- treating cancer
- immune diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661203P | 2012-06-18 | 2012-06-18 | |
PCT/US2013/045266 WO2013191965A1 (en) | 2012-06-18 | 2013-06-11 | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2861599T3 true DK2861599T3 (da) | 2020-03-02 |
Family
ID=48692669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13731218.7T DK2861599T3 (da) | 2012-06-18 | 2013-06-11 | Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160045503A1 (da) |
EP (1) | EP2861599B1 (da) |
JP (1) | JP6189945B2 (da) |
KR (1) | KR102150432B1 (da) |
CN (1) | CN104487441B (da) |
AU (1) | AU2013277582B2 (da) |
CA (1) | CA2874461C (da) |
DK (1) | DK2861599T3 (da) |
ES (1) | ES2776175T3 (da) |
HK (1) | HK1209103A1 (da) |
MX (1) | MX368112B (da) |
WO (1) | WO2013191965A1 (da) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2836410C (en) | 2011-05-17 | 2019-08-20 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
MY187999A (en) | 2012-06-04 | 2021-11-08 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
KR102203990B1 (ko) | 2012-09-10 | 2021-01-18 | 프린시피아 바이오파마, 인코퍼레이티드 | 키나제 저해제로서의 피라졸로피리미딘 화합물 |
WO2014078578A1 (en) * | 2012-11-15 | 2014-05-22 | Pharmacyclics, Inc. | Pyrrolopyrimidine compounds as kinase inhibitors |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US9624224B2 (en) | 2013-09-30 | 2017-04-18 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
JP2017507963A (ja) | 2014-03-12 | 2017-03-23 | ノバルティス アーゲー | Btk阻害薬とakt阻害薬を含む組み合わせ |
CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
WO2016019233A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
WO2016079693A1 (en) | 2014-11-19 | 2016-05-26 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
EP3233103B1 (en) * | 2014-12-18 | 2020-10-14 | Principia Biopharma Inc. | Treatment of pemphigus |
CA2971109A1 (en) * | 2014-12-24 | 2016-06-30 | Principia Biopharma Inc. | Site specific dosing of a btk inhibitor |
MA41265B1 (fr) * | 2014-12-24 | 2023-05-31 | Principia Biopharma Inc | Compositions pour administration de médicaments iléo-jéjunal. |
TW202315634A (zh) | 2015-03-03 | 2023-04-16 | 美商製藥公司 | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
CN106146511A (zh) * | 2015-04-03 | 2016-11-23 | 安润医药科技(苏州)有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
WO2016154998A1 (zh) * | 2015-04-03 | 2016-10-06 | 安润医药科技(苏州)有限公司 | 吡唑并嘧啶衍生物、制备方法、药物组合物及用途 |
KR102552653B1 (ko) * | 2015-06-03 | 2023-07-07 | 프린시피아 바이오파마, 인코퍼레이티드 | 티로신 키나제 억제제 |
WO2016210165A1 (en) * | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
WO2017027883A1 (en) | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
KR20180109842A (ko) | 2015-09-16 | 2018-10-08 | 록쏘 온콜로지, 인코포레이티드 | 화합물 |
CA3008488C (en) | 2015-12-16 | 2023-10-10 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
EP4321513A2 (en) | 2016-03-28 | 2024-02-14 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
CN111153906B (zh) * | 2016-05-16 | 2020-09-11 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物 |
CN115054586A (zh) | 2016-06-29 | 2022-09-16 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
CN110483521B (zh) * | 2018-05-14 | 2022-06-07 | 杭州和正医药有限公司 | 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用 |
KR102300092B1 (ko) * | 2018-11-05 | 2021-09-09 | 가톨릭대학교 산학협력단 | pH 민감성 탄소 나노입자, 이의 제조방법 및 이를 이용한 약물전달 |
CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药(上海)有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
WO2021029467A1 (en) * | 2019-08-14 | 2021-02-18 | Sam Chun Dang Pharm. Co., Ltd. | A solid dosage form for orally administration |
CN110448557A (zh) * | 2019-09-05 | 2019-11-15 | 黄筱茜 | 抗凝血药达比加群酯的新药用途 |
KR20220124753A (ko) | 2020-01-08 | 2022-09-14 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카보닐]-4,4-디메틸펜트-2-엔니트릴을 포함하는 국소 약제학적 조성물 |
CA3194724A1 (en) * | 2020-10-05 | 2022-04-14 | Dana-Farber Cancer Institute, Inc. | Potent and selective inhibitors of her2 |
WO2022109001A1 (en) | 2020-11-18 | 2022-05-27 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
EP4267186A1 (en) * | 2020-12-23 | 2023-11-01 | Yeda Research and Development Co. Ltd | Methacrylamides protein binders and uses thereof |
KR20230167914A (ko) * | 2022-06-03 | 2023-12-12 | 주식회사 서흥 | 장용성 경질캡슐의 제조를 위한 밴딩 용액과 이를 이용하여 제조한 장용성 경질캡슐 |
WO2023242597A1 (en) * | 2022-06-16 | 2023-12-21 | Amphista Therapeutics Limited | Bifunctional molecules for targeted protein degradation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
NZ601278A (en) * | 2006-09-22 | 2013-09-27 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
CN102711765A (zh) | 2009-11-16 | 2012-10-03 | 加利福尼亚大学董事会 | 激酶抑制剂 |
BR112013029508B1 (pt) * | 2011-05-17 | 2022-05-03 | Principia Biopharma, Inc. | Composto, composição farmacêutica, e, uso do referido composto |
CA2836410C (en) * | 2011-05-17 | 2019-08-20 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
-
2013
- 2013-06-11 DK DK13731218.7T patent/DK2861599T3/da active
- 2013-06-11 AU AU2013277582A patent/AU2013277582B2/en active Active
- 2013-06-11 MX MX2014015346A patent/MX368112B/es active IP Right Grant
- 2013-06-11 CA CA2874461A patent/CA2874461C/en active Active
- 2013-06-11 ES ES13731218T patent/ES2776175T3/es active Active
- 2013-06-11 JP JP2015517370A patent/JP6189945B2/ja active Active
- 2013-06-11 KR KR1020157000923A patent/KR102150432B1/ko active IP Right Grant
- 2013-06-11 CN CN201380031739.2A patent/CN104487441B/zh active Active
- 2013-06-11 WO PCT/US2013/045266 patent/WO2013191965A1/en active Application Filing
- 2013-06-11 EP EP13731218.7A patent/EP2861599B1/en active Active
- 2013-06-11 US US14/403,744 patent/US20160045503A1/en not_active Abandoned
-
2015
- 2015-10-02 HK HK15109678.3A patent/HK1209103A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013191965A1 (en) | 2013-12-27 |
US20160045503A1 (en) | 2016-02-18 |
CA2874461C (en) | 2021-10-12 |
ES2776175T3 (es) | 2020-08-14 |
JP6189945B2 (ja) | 2017-08-30 |
EP2861599B1 (en) | 2019-12-18 |
AU2013277582A1 (en) | 2015-01-22 |
MX2014015346A (es) | 2015-03-05 |
MX368112B (es) | 2019-09-18 |
CN104487441B (zh) | 2018-06-01 |
CN104487441A (zh) | 2015-04-01 |
AU2013277582B2 (en) | 2017-11-30 |
HK1209103A1 (en) | 2016-03-24 |
JP2015519401A (ja) | 2015-07-09 |
CA2874461A1 (en) | 2013-12-27 |
EP2861599A1 (en) | 2015-04-22 |
KR102150432B1 (ko) | 2020-09-01 |
KR20150023752A (ko) | 2015-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2861599T3 (da) | Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme | |
LTPA2019519I1 (lt) | Makrocikliniai dariniai, skirti proliferacinių ligų gydymui | |
DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
DK2909196T3 (da) | Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi | |
DK2838900T3 (da) | Forbindelser og fremgangsmåder til antiviral behandling | |
DK2909198T3 (da) | Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi | |
DK3027208T3 (da) | Cancerdiagnose og -terapi, der involverer cancerstamceller | |
DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
BR112014032105A2 (pt) | método para o tratamento de câncer | |
DK3266456T3 (da) | Kombinationer af liposomal irinotecan, 5-fu og leucovorin til behandlingen af pancreaskræft | |
DK2956483T3 (da) | Terapeutisk og diagnostisk mål for cancer omfattende dll3-bindende reagenser | |
DK3492455T3 (da) | 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer | |
DK3179393T3 (da) | Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft | |
DK2970205T3 (da) | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf | |
BR112014007603A2 (pt) | métodos de tratamento do câncer | |
DK2850202T3 (da) | Fremgangsmåder og grupper | |
DK2790738T3 (da) | Biomarkører for kollateral geninaktivering og mål for cancerterapi | |
DK2861273T3 (da) | Anvendelse af heparin og kulhydrater til behandling af cancer. | |
DK2994533T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
DK3030557T3 (da) | Hidtil ukendte phtalazinonderivater og fremgangsmåde til fremstilling deraf | |
DK2898865T3 (da) | Pleje-fremgangsmåde og plejerobot, der anvendes ved denne | |
DK2914261T3 (da) | Syntetisk letalitet og behandling af cancer | |
BR112013011659A2 (pt) | métodos de tratamento do câncer | |
DK2883954T3 (da) | Peptidbibliotek og anvendelse deraf |